Benzinga | Aug 25, 2021 06:11AM EDT

HC Wainwright & Co. Upgrades Catabasis Pharmaceuticals to Buy, Announces $13 Price Target

HC Wainwright & Co. analyst Joseph Pantginis upgrades Catabasis Pharmaceuticals (NASDAQ:CATB) from Neutral to Buy and announces $13 price target.